The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
The CD19-targeted rare disease medicine Uplizna was one of the crown jewels in Amgen’s $27.8 billion buyout of Horizon ...
Amgen said on Wednesday its drug helped to reduce the risk of flares in patients with an immune system-related condition, ...
Uplizna therapy reaches main goal in Phase 3 trial for IgG4-RD, cutting the risk of flare by 87% with no new safety events.
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin ...